Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC-151 Injection in Healthy Chinese Participants
NCT07376200Phase 1Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in diabetes mellitus (DM) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse events, Electrocardiogram parameter (Heart rate) and 7 more. Started Feb 2026; status: recruiting.
02
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07376200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376200.